Loading patent…
AssigneeBoard of Trustees of the University of Arkansas
InventorsThomas Dag Horn, Sandra Marchese Johnson
Estimating the term…
The present immunotherapy relates to a method of treating epithelial tumors and the pharmaceutical compositions and kits useful in treating such tumors. The immunotherapy comprises injecting an effective amount of a pharmaceutical composition containing at least one antigen into the tumor, wherein the antigen is selected for inducing or having the ability to induce a cutaneous delayed type hypersensitivity (DTH) response in the subject prior to the injection of the antigen into the tumors. This immunotherapy is particularly useful in treating epithelial tumors, such as warts or verrucae, that are induced by or related to papillomavirus. Antigens useful in the present immunotherapy are anergy panel antigens, such as killed mumps virus, candida extract, trichophyton extract or comparable antigenic extracts. Additionally, the method optionally includes the injection of an effective amount of at least one cytokine or colony stimulating factor into the tumor either simultaneously with or sequentially to the injection of the antigen. The subject treated by the present immunotherapy is preferably a mammal selected from a human, canine, bovine, feline, equine, ovine or rabbit subject.
A method of treating at least one benign epithelial tumor in a subject comprising injecting an effective amount sufficient to cause regression of said tumor of a pharmaceutical composition comprising an antigen selected from the group consisting of mumps, candida, trichophyton and a combination thereof, into at least one of said tumor in said subject, wherein said tumor is caused by a papilloma virus, and wherein said antigen induces or is capable of inducing a cutaneous delayed type hypersensitivity response in said subject.
Dependencies are inferred from the claim text.